Cardiac effects associated with breast cancer treatment appear lower with dose-dense

[News]

A new pilot study by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) found that breast cancer patients can be treated safely with a "dose-dense" regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin), a drug that has previously been shown to cause cardiac toxicity.

More... (http://www.news-medical.net/?id=36079)